Technology | Ultrasound Imaging | January 12, 2017

GE Introduces Its First App-Based, Pocket-Sized Dual-Probe Ultrasound

Vscan Extend offers high image quality, wireless connectivity and cloud integration with a touch-screen interface

GE Healthcare, Vscan Extend, app-based ultrasound, dual-probe, RSNA 2017
GE Healthcare, Vscan Extend, app-based ultrasound, portable, paramedic, RSNA 2017

January 12, 2017 — GE Healthcare unveiled its new generation of pocket-sized, dual-probe ultrasound, the Vscan Extend. From the hospital and ambulance to more rural environments, Vscan Extend uses high image quality and wireless connectivity1 to help users increase clinical confidence and improve patient care.

“Vscan Extend completely changes the game in how we are able to use ultrasound both inside and outside hospitals,” said Guy Lloyd, M.D., clinical cardiologist and lead for echocardiography at Barts Heart Centre in London. “For the first time on handheld ultrasounds, we can pre-populate the device with images thanks to the DICOM integration, which then cascades the images through PACS [picture archiving and communication systems], enabling seamless collaboration with colleagues in our hospital system. As a result, we are able to provide rapid diagnostics to patients, increase efficiency and save on cost.” 

Vscan Extend offers an intuitive touch screen and weighs just 406 grams. The system offers smooth integration with hospitals’ DICOM systems2 to complement existing documentation and reporting solutions along with cloud-based image storage and communication3. Vscan Extend is GE Healthcare’s first ultrasound system to leverage the GE Marketplace that offers applications with a range of capabilities, such as assessing heart failure patients, measuring bladder volume, and offering cloud-based image communication. The system comes with high-level data security standards ensuring encrypted data both at rest and on the move. 

Vscan Extend is not currently available in all countries. Today, it is commercially available in Europe; it will also be available in the United States by the end of January. 

The device has been verified for limited use outside of professional healthcare facilities and has not been evaluated for use during transport. Use is restricted to environmental properties described in the user manual.

For more information: www.gehealthcare.com 

1. Valid for systems with Wi-Fi configurations.

2. Valid for systems with DICOM configurations.

3. The Vscan Extend app includes the interface to Tricefy, a cloud-based case exchange solution that is separately provided by Trice Imaging. Customers may elect to try Tricefy via trial period by entering into an agreement with Trice Imaging. Trice Imaging bears sole responsibility for the Tricefy Uplink app and Tricefy cloud solution.

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle